🔗 Share this article WHO Sounds Warning Over Critical Scarcity of Weight-Loss Medications Under one in 10 patients eligible to benefit from GLP-1 drugs like Wegovy can access them, caution the WHO as it releases its initial recommendations on the medications. Considering over a billion individuals worldwide now classified as obese, it is advocating for more widespread and fairer availability to these injectable treatments. According to forecasts, in excess of 2,000,000,000 will be living with obesity by 2030 if no action is taken. "Our latest guidelines recognises that excess weight is a long-term condition that can be managed with comprehensive and ongoing care," said WHO director-general Tedros Adhanom Ghebreyesus. Substantial prices, limited production capacity, and logistical bottlenecks are significant obstacles to universal availability to the injections that can assist patients in reducing significant weight, says the body. Weight-Loss Drug Shortage Despite the present most optimistic case, the production of such drugs might only reach around 100 million people – less than 10% of the global need, according to the health organization. The recommendation encourages countries and companies to expand access, via approaches such as voluntary licensing. The intellectual property rights on a key compound – the main component of a leading brand – is set to lapse in a number of nations in 2026. How Weight-Loss Drugs Operate GLP-1 drugs imitate a biological compound to reduce digestion speed, reduce hunger and enhance the sense of being full so individuals eat less. Patients commonly see weight reduction in the initial weeks of beginning the once-weekly jabs. Studies suggests people may regain a significant portion after a year of halting the drug, as their normal food cravings come back. Being carrying excess weight raises your risk for experiencing medical conditions, such as type 2 diabetes, heart disease, brain attack, and some malignancies. Excess weight concerns people in all nations and was linked to 3.7 million fatalities worldwide in 2024, per the health agency.
Under one in 10 patients eligible to benefit from GLP-1 drugs like Wegovy can access them, caution the WHO as it releases its initial recommendations on the medications. Considering over a billion individuals worldwide now classified as obese, it is advocating for more widespread and fairer availability to these injectable treatments. According to forecasts, in excess of 2,000,000,000 will be living with obesity by 2030 if no action is taken. "Our latest guidelines recognises that excess weight is a long-term condition that can be managed with comprehensive and ongoing care," said WHO director-general Tedros Adhanom Ghebreyesus. Substantial prices, limited production capacity, and logistical bottlenecks are significant obstacles to universal availability to the injections that can assist patients in reducing significant weight, says the body. Weight-Loss Drug Shortage Despite the present most optimistic case, the production of such drugs might only reach around 100 million people – less than 10% of the global need, according to the health organization. The recommendation encourages countries and companies to expand access, via approaches such as voluntary licensing. The intellectual property rights on a key compound – the main component of a leading brand – is set to lapse in a number of nations in 2026. How Weight-Loss Drugs Operate GLP-1 drugs imitate a biological compound to reduce digestion speed, reduce hunger and enhance the sense of being full so individuals eat less. Patients commonly see weight reduction in the initial weeks of beginning the once-weekly jabs. Studies suggests people may regain a significant portion after a year of halting the drug, as their normal food cravings come back. Being carrying excess weight raises your risk for experiencing medical conditions, such as type 2 diabetes, heart disease, brain attack, and some malignancies. Excess weight concerns people in all nations and was linked to 3.7 million fatalities worldwide in 2024, per the health agency.